Navigation Links
Alseres Pharmaceuticals' Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
Date:9/24/2007

n subgroups of patients treated with Cethrin are analyzed, patients with cervical injuries exhibit a more pronounced response compared to patients with thoracic injuries, showing a conversion rate that is six to seven times greater than the full patient group treated with the standard of care reported in the publication above. In patients with cervical injuries, the interim efficacy data also suggest that the response rate observed is dose dependent at the doses tested to date.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world- class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre- clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. Our lead product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Safe harbor

The foregoing release
'/>"/>

SOURCE Alseres Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 2015 This report analyzes the worldwide markets for ... following Segments: Standard Intraocular Lenses, and Premium Intraocular Lenses. The ... Canada , Japan , ... Latin America , and Rest of World. Annual estimates ... Also, a seven-year historic analysis is provided for these markets. ...
(Date:5/28/2015)... , May 28, 2015 ... has announced the addition of the  "North ... And Forecasts (2014 - 2019)"  report to ... Ultrasound is a type of ... look at body parts and structures inside ...
(Date:5/28/2015)... May 28, 2015 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... Ronald A. Martell , to the position of Executive ... the KaloBios Board of Directors. In this new role, ... team to refine and execute on the strategic plan ... developing therapeutics for orphan oncology indications with high unmet ...
Breaking Medicine Technology:World Intraocular Lenses Industry 2World Intraocular Lenses Industry 3World Intraocular Lenses Industry 4World Intraocular Lenses Industry 5World Intraocular Lenses Industry 6World Intraocular Lenses Industry 7World Intraocular Lenses Industry 8World Intraocular Lenses Industry 9World Intraocular Lenses Industry 10World Intraocular Lenses Industry 11World Intraocular Lenses Industry 12World Intraocular Lenses Industry 13World Intraocular Lenses Industry 14World Intraocular Lenses Industry 15World Intraocular Lenses Industry 16World Intraocular Lenses Industry 17World Intraocular Lenses Industry 18World Intraocular Lenses Industry 19World Intraocular Lenses Industry 20World Intraocular Lenses Industry 21World Intraocular Lenses Industry 22World Intraocular Lenses Industry 23World Intraocular Lenses Industry 24World Intraocular Lenses Industry 25World Intraocular Lenses Industry 26North America Ultrasound Devices Market Report 2014-2019 - Technology and Applications 2KaloBios Appoints Ronald A. Martell Executive Chairman 2KaloBios Appoints Ronald A. Martell Executive Chairman 3KaloBios Appoints Ronald A. Martell Executive Chairman 4KaloBios Appoints Ronald A. Martell Executive Chairman 5
... Adeona Pharmaceuticals, Inc. (AMEX: AEN ), a ... diseases, announced today that it will hold a conference ... study evaluating reaZin for the dietary management ... April 15, 2011, at 8:00 a.m. (HAST)/2:00 p.m. (EDT). ...
... BATESVILLE, Ind., April 14, 2011 Hill-Rom (NYSE: ... on Tuesday, May 24, 2011 in New York City.  John ... executives will host investors and analysts to discuss the company,s ... webcast the entire conference beginning at 9 a.m. EDT on ...
Cached Medicine Technology:Adeona to Host Conference Call 2
(Date:5/29/2015)... Javlin continues to fulfill its worldwide ... a larger team, with the intention to better serve ... in the U.S. and Canada. , Javlin Inc., the ... growth in 2014 with its strongest earnings to date, ... platform, CloverETL. To accelerate further progress and ensure exceptional ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 The annual aesthetic ... Surgery (ASAPS), was held in Montreal from May 14-19th. ... for aesthetic professionals from around the world; dedicating itself exclusively ... the many renowned plastic surgeons to attend this ... the six-day event, Dr. Vitenas was given the honor of ...
(Date:5/29/2015)... Healthpointe is excited to announce that they are now ... in Orange County. The Supartz Therapy is a cost-effective, ... for patients with osteoarthritis, and will be administered by ... of Healthpointe. Supartz is an injection of made from ... a natural substance found in joint cartilage. Also known ...
(Date:5/29/2015)... Metamora, Michigan (PRWEB) May 29, 2015 ... region and can cause significant physical, sexual, and psychological ... life altering disorder of Vulvodynia. The actual diagnosis is ... Excellence in Endometriosis, they realize that this problem can ... is experiencing any of these symptoms, they need to ...
(Date:5/29/2015)... The popular all-natural supplement brand, Liporidex, ... Select Program that gives bonuses to members for their ... 100 members per year, lucky members who are selected ... fitness experts at Nuretix Research, and get exclusive benefits ... they attain and maintain their weight loss and fitness ...
Breaking Medicine News(10 mins):Health News:Growth of Data Integration Platform CloverETL Continues in North America 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 2Health News:Dr. Paul Vitenas Presents at 2015 Aesthetic Meeting 3Health News:Healthpointe is Now Offering Supartz Joint Fluid Therapy at their Anaheim Clinic and La Mirada Clinic. 2Health News:Liporidex, a Sports Nutrition Supplement Brand, Is Searching For Members For Their Exclusive L-Style Select Program Which Rewards Members For Their Achievements 2
... comes a new study that links breakdown of myelin ... of California, Los Angeles (UCLA) researchers showed that genetic ... breakdown, may prove useful in assessing treatments for prevention ... a process uniquely built up in humans, arguably is ...
... The New Women's Health Initiative (WHI) suggests, a prolonged ... carbohydrates results in negligible weight gain. // ... postmenopausal women Vis a Vis variations in consumed foods ... advised to reduce the fat consumption to 20% of ...
... body cavity rather than the conventional intravenous route, seems to ... cancer patients, according to a latest study. // ... among American women. In line with the above finding, the ... all ovarian cancer patients. ,This new treatment modality ...
... help in slowing down the progress of Alzheimer's disease, ... and Chile. The healthy brain // ... their study, to be published in the American Chemical ... surgery, has the potential to destroy beta-amyloid fibrils and ...
... Rotateq and Rotarix in more than 1, 30, 000 ... The vaccines have been found to be 98% and ... 1/3rd of all hospital infections worldwide. ,A ... 1990’s. This however, was withdrawn from the market owing ...
... A leaflet claiming that traditional Chinese medicine was safer ... code in the UK, an industry watchdog said on ... essential treatment from qualified doctors for serious medical conditions, ... produced by Ever Well Ltd, also claimed that serious ...
Cached Medicine News:Health News:Death Risk Of Ovarian Cancer Reduced By Intraperitoneal Chemotherapy 2Health News:Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection 2Health News:Chinese medicine leaflet broke advertising code 2
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: